Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections

NCT ID: NCT06096025

Last Updated: 2025-07-04

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-06-23
• Study Completion Date: 2026-06-23

Brief Summary

Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.

Detailed Description

The Infectious Diseases Society of America (IDSA) guidelines for CAP management advocate for short courses of antibiotics for CAP treatment. However, it does not address duration of therapy for common CAP pathogens such as S. pneumoniae when associated with blood stream infections (BSI). 3

Currently, GP bacteremia duration of therapy typically ranges from 7 to 14 days based on IDSA guideline recommendations for Staphylococcus aureus bacteremia with no further definitive consensus.4 Additionally, lack of data and randomized clinical trials on the efficacy and safety of short compared to long treatment duration have led to variability in practice. Most randomized clinical trials as well as retrospective studies on treatment duration, have been conducted mainly in gram-negative BSI

Conditions

Streptococcus Pneumoniae

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: RETROSPECTIVE

Interventions

pneumoniae bacteremia therapy

To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.

Intervention Type: DRUG

Other Intervention Names

Total antibiotic treatment duration

Eligibility Criteria

Inclusion Criteria

• • ≥18 years of age

• S. pneumoniae isolated from ≥1 blood cultures
• Active IV antibiotic therapy within 48 hours of the first positive blood culture(7,8)
• Clinical stability by day 10 of therapy

Exclusion Criteria

• • Treatment duration <5 days or >16 days

• Death before completion of therapy (<10 days vs. ≥ 10 days )
• Polymicrobial BSI
• Invasive infection caused by S. pneumoniae (endocarditis, meningitis, and lung abscess)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Methodist Health System

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Matthew Crotty, PharmD

Role: PRINCIPAL_INVESTIGATOR

Methodist Midlothian Medical Center

Locations

Methodist Dallas Medical Center

Dallas, Texas, United States

Countries

United States

Other Identifiers

026.PHA.2023.A

Identifier Type: -

Identifier Source: org_study_id